Issue 000 | U.S. Pilot | US

ASBP

Aspire Biopharma Holdings, Inc.

Passing Verified 10-Q | 2026-05-15 Filing currency: USD
Margin of Safety 73.1%

GNNI internal calculation. Market context inputs are retained internally and are not displayed.

Current Assets
7,117,147USD
Total Liabilities
3,248,684USD
NCAV
3,868,463USD
Cash
5,857,024USD
NCAV per share
23.10USD/share
Evidence
4 annual | 21 quarterly

Business Profile

Checklist-driven facts extracted from filing text. Missing fields stay visible.

Business profile not generated.

Run python -m application.cli.business_profile run --market US --one ASBP, then regenerate the site.

Known Unknowns

Medium | Share Count

Issue 000 does not yet evaluate share count trend or post-filing dilution beyond Mary's screening flags.

Low | Classification

U.S. Pilot rows are surfaced for source inspection and may still need manual business classification review.

Annual Financials

Latest annual periods, newest first. Missing cells render as n/a.

Metric
2025-12-31
10-K
USD
2024-12-31
10-K
USD
2023-12-31
10-K
USD
2022-12-31
10-K
USD
Revenue 6,202 n/a n/a n/a
Operating Income -19,351,291 -1,210,871 n/a n/a
Net Income -24,480,848 -12,537,472 4,464,079 3,340,238
Cash From Operations -4,923,488 -2,054,680 -653,107 -1,408,786
Capex n/a n/a n/a n/a
Free Cash Flow n/a n/a n/a n/a
Cash And Equivalents 1,003,904 n/a n/a n/a
Accounts Receivable n/a n/a n/a n/a
Inventory 253,160 n/a n/a n/a
Total Current Assets 1,312,166 45,842 81,223 1,097,752
Total Assets 1,312,166 6,714,364 19,982,392 300,182,005
Total Current Liabilities 7,592,833 15,616,047 403,328 303,323
Total Liabilities 7,688,495 15,616,047 403,328 11,115,823
Shareholders Equity -6,376,329 -15,570,205 -322,105 -9,937,901
Shares Outstanding 3,533,408 690,044 n/a n/a
Shares Outstanding Diluted n/a n/a n/a n/a
Weighted Avg Shares Diluted 1,494,956 689,913 n/a n/a
Weighted Avg Shares Basic 1,494,956 689,913 n/a n/a
Quarterly Financials

Latest quarterly periods, newest first. Periods are shown only when Data Vault has them.

Metric
2026-03-31
10-Q
USD
2025-12-31
10-K
USD
2025-09-30
10-Q
USD
2025-06-30
10-Q
USD
2025-03-31
10-Q
USD
2024-12-31
10-K
USD
2024-09-30
10-Q
USD
2024-06-30
10-Q
USD
2024-03-31
10-Q
USD
2023-12-31
10-K
USD
2023-12-31
10-K
USD
2023-12-31
10-K
USD
2023-09-30
10-Q
USD
2023-06-30
10-Q
USD
2023-03-31
10-Q
USD
2022-12-31
10-K
USD
2022-12-31
10-K
USD
2022-12-31
10-K
USD
2022-09-30
10-Q
USD
2022-06-30
10-Q
USD
2022-03-31
10-Q
USD
Revenue 28,353 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income -1,646,169 n/a -1,945,387 n/a -15,556,480 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Net Income -3,222,892 -4,707,734 -1,850,493 -1,981,293 -15,941,328 -8,931,094 -537,019 -602,258 -2,467,101 -150,913 -150,913 -150,913 -69,258 1,811,817 2,872,433 2,109,461 2,109,461 2,109,461 1,197,910 120,693 -87,826
Cash From Operations -3,038,522 -927,841 -1,103,809 -1,140,310 -1,751,528 772,124 25,504 -592,315 -2,259,993 -156,128 -156,128 -156,128 -124,921 -189,951 -182,107 -35,870 -35,870 -35,870 -46,622 -38,371 -1,287,923
Capex n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Free Cash Flow n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cash And Equivalents 5,857,024 1,003,904 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Current Assets 7,117,147 1,312,166 2,403,129 989,422 1,965,514 45,842 61,809 342,973 65,577 81,223 81,223 81,223 253,362 546,144 906,455 1,097,752 1,097,752 1,097,752 1,146,486 1,208,880 1,263,023
Total Liabilities 3,248,684 7,688,495 13,870,407 10,606,207 8,918,256 15,616,047 6,572,881 6,240,280 2,633,383 403,328 403,328 403,328 316,316 284,356 11,168,921 11,115,823 11,115,823 11,115,823 11,001,205 10,958,966 10,864,256
Shares Outstanding 167,470 3,533,408 49,525,970 49,525,970 48,900,970 690,044 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding Diluted n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Weighted Avg Shares Diluted 156,685 1,494,956 49,525,970 n/a 31,575 689,913 27,601,767 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Weighted Avg Shares Basic 156,685 1,494,956 49,525,970 n/a 31,575 689,913 27,601,767 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Audit Trail

NCAV Audit

Official-source inputs remain linked to filing provenance. Derived values are labeled as such.

Input Value Source concept Filing period Confidence Provenance
Current Assets 7,117,147USD us-gaap:AssetsCurrent 2026-03-31 1.00 sec/companyfacts/cik=0001847345/companyfacts.json
D:\Projects\The Data Vault\objects\sec\companyfacts\cik=0001847345\companyfacts.json
Total Liabilities 3,248,684USD us-gaap:Liabilities 2026-03-31 1.00 sec/companyfacts/cik=0001847345/companyfacts.json
D:\Projects\The Data Vault\objects\sec\companyfacts\cik=0001847345\companyfacts.json
Cash 5,857,024USD us-gaap:CashAndCashEquivalentsAtCarryingValue 2026-03-31 1.00 sec/companyfacts/cik=0001847345/companyfacts.json
D:\Projects\The Data Vault\objects\sec\companyfacts\cik=0001847345\companyfacts.json
Shares Outstanding 167,470 us-gaap:CommonStockSharesOutstanding 2026-03-31 1.00 sec/companyfacts/cik=0001847345/companyfacts.json
D:\Projects\The Data Vault\objects\sec\companyfacts\cik=0001847345\companyfacts.json
NCAV 3,868,463USD derived 2026-03-31 n/a company-evidence-v1 | total_current_assets - total_liabilities
NCAV per share 23.10USD derived 2026-03-31 n/a company-evidence-v1 | NCAV / shares_outstanding
Margin of Safety 73.1% derived 2026-03-31 n/a gnni_publication_pack | internal_discount

NCAV = total_current_assets - total_liabilities | NCAV per share = NCAV / shares_outstanding

Source Provenance

Data Source
Data Vault
Data Vault Root
D:\Projects\The Data Vault
CIK
0001847345
Company ID
n/a
Selected Annual Source
D:\Projects\The Data Vault\objects\sec\companyfacts\cik=0001847345\companyfacts.json
Selected Quarterly Source
D:\Projects\The Data Vault\data\objects\sec\companyfacts\cik=0001847345\companyfacts.json
Statement Extractor
companyfacts-screener-v1
View Extractor
companyfacts-screener-v1
Source Accession Count
15
Imported At
2026-07-04T23:04:24+00:00
Rendered At
2026-07-05T09:06:29+00:00

Run Audit

Mary Run
1ec055d81d1a42a39490a83bb9e1f22f
Mary As Of
2026-07-03
Accession
0001493152-26-023802
CIK
0001847345
Mary Filing Date
2026-05-15
Filing Currency
USD
Internal Discount
73.1%
Source State
Verified
Market Context
Not Displayed
Market Policy
internal_only_not_redistributed
Share Trend
Not Evaluated
Dilution
Needs Review

mary_run=1ec055d81d1a42a39490a83bb9e1f22f; mary_as_of=2026-07-03; mary_filing_date=2026-05-15; mary_accession=0001493152-26-023802; mary_cik=0001847345; gnni_supporting_filing_date=2026-05-15; internal_discount=0.731162; mary_reason=Mary's deterministic net-net screen flagged this candidate. The internal discount is shown; raw market-data fields are not published in this pilot.

Back to Register Archive